Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00028366
Status:
COMPLETED
Last Update Posted:
2021-11-01
First Post:
2001-12-27
Brief Title:
Dual Versus Triple Protease Inhibitor Combinations Including Ritonavir in HIV Infected People
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Randomized Comparative Study of LopinavirRitonavir Versus GW433908 and Ritonavir Versus LopinavirRitonavir and GW433908 In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors in HIV-1-Infected Subjects With Virologic Treatment Failure
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ritonavir RTV is a protease inhibitor PI commonly used to increase drug levels of other PIs in HIV drug treatment The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors PIs with 2 combinations that include RTV and another PI This study also will compare the effectiveness safety tolerability and drug levels in the blood of these anti-HIV drug combinations
Detailed Description:
A substantial proportion of patients on antiretroviral therapy do not achieve sustained suppression of HIV viral load Developing strategies to improve responses to subsequent regimens is an important objective for the management of patients with HIV infection Increasing the potency of regimens by using a pharmacoenhancer such as RTV is of interest RTV is used widely to increase plasma concentrations of PIs but there is little efficacy and tolerability data about different RTV-enhanced PIs The efficacy and tolerability of a triple PI regimen will be compared to dual PI regimens dual PI regimens will also be compared to each other
In Step 1 patients will be selectively randomized based on prior exposure to the study drugs and enrolled into 1 of 3 study arms Patients in Arm A will receive lopinavir LPVRTV in combination with TDF and 1 or 2 other NRTIs patients in Arm B will receive fosamprenavir plus RTV in combination with TDF and 1 or 2 other NRTIs Arm C patients were to receive LPVRTV plus fosamprenavir in combination with TDF and 1 or 2 other NRTIs Because interim study results indicated that mean PI levels for patients in Arm C were unacceptably low Arm C patients will now either drop LPVRTV and add RTV or drop fosamprenavir from their regimens
The study will last 24 to 48 weeks Medications and clinical assessment and blood collection will be performed at 2 weeks prior to entry entry and Weeks 2 4 8 12 16 24 32 40 and 48 Blood samples to test for amprenavir APV and LPV pharmacokinetics will be collected at Weeks 12 24 48 and at confirmed virologic failure visits In substudy A5147S intensive 12-hour pharmacokinetic sampling for APV LPV and RTV will be conducted The first 20-25 patients enrolled in each arm will be enrolled in the substudy 14-28 days after starting study treatment
In Step 1 patients will be selectively randomized based on prior exposure to the study drugs and enrolled into 1 of 3 study arms Patients in Arm A will receive lopinavir LPVRTV in combination with TDF and 1 or 2 other NRTIs patients in Arm B will receive fosamprenavir plus RTV in combination with TDF and 1 or 2 other NRTIs Arm C patients were to receive LPVRTV plus fosamprenavir in combination with TDF and 1 or 2 other NRTIs Because interim study results indicated that mean PI levels for patients in Arm C were unacceptably low Arm C patients will now either drop LPVRTV and add RTV or drop fosamprenavir from their regimens
The study will last 24 to 48 weeks Medications and clinical assessment and blood collection will be performed at 2 weeks prior to entry entry and Weeks 2 4 8 12 16 24 32 40 and 48 Blood samples to test for amprenavir APV and LPV pharmacokinetics will be collected at Weeks 12 24 48 and at confirmed virologic failure visits In substudy A5147S intensive 12-hour pharmacokinetic sampling for APV LPV and RTV will be conducted The first 20-25 patients enrolled in each arm will be enrolled in the substudy 14-28 days after starting study treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Substudy ACTG A5147S | Registry Identifier | DAIDS ES | None |
| 10681 | REGISTRY | None | None |
| ACTG A5143 | None | None | None |
| AACTG A5143 | None | None | None |
| Substudy AACTG A5147S | None | None | None |